277 related articles for article (PubMed ID: 8637885)
1. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Pinski J; Vadillo-Buenfil M; Groot K
Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2398-402. PubMed ID: 8637885
[TBL] [Abstract][Full Text] [Related]
2. Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.
Halmos G; Schally AV
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):961-5. PubMed ID: 11805337
[TBL] [Abstract][Full Text] [Related]
3. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV
Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Kahan Z
Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
[TBL] [Abstract][Full Text] [Related]
5. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH.
Kovacs M; Schally AV; Csernus B; Rekasi Z
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1829-34. PubMed ID: 11172036
[TBL] [Abstract][Full Text] [Related]
6. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
Bokser L; Srkalovic G; Szepeshazi K; Schally AV
Neuroendocrinology; 1991 Aug; 54(2):136-45. PubMed ID: 1662786
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).
Pinski J; Schally AV; Yano T; Groot K; Srkalovic G; Serfozo P; Reissmann T; Bernd M; Deger W; Kutscher B
Int J Pept Protein Res; 1995 May; 45(5):410-7. PubMed ID: 7591480
[TBL] [Abstract][Full Text] [Related]
8. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
Srkalovic G; Bokser L; Radulovic S; Korkut E; Schally AV
Endocrinology; 1990 Dec; 127(6):3052-60. PubMed ID: 2174343
[TBL] [Abstract][Full Text] [Related]
9. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats.
Horvath JE; Bajo AM; Schally AV; Kovacs M; Herbert F; Groot K
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15048-53. PubMed ID: 12409615
[TBL] [Abstract][Full Text] [Related]
11. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
Kovacs M; Schally AV
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12197-202. PubMed ID: 11593037
[TBL] [Abstract][Full Text] [Related]
12. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
Lamharzi N; Halmos G; Jungwirth A; Schally AV
Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
[TBL] [Abstract][Full Text] [Related]
13. Luteinizing hormone-releasing hormone antagonist Cetrorelix regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in rat ovary, breast and pituitary.
Collado B; Carmena MJ; Cortés J; Schally AV; Prieto JC
Int J Oncol; 2004 Mar; 24(3):725-30. PubMed ID: 14767559
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75).
Gonzalez-Barcena D; Vadillo Buenfil M; Garcia Procel E; Guerra-Arguero L; Cardenas Cornejo I; Comaru-Schally AM; Schally AV
Eur J Endocrinol; 1994 Sep; 131(3):286-92. PubMed ID: 7921214
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat.
Ayalon D; Farhi Y; Comaru-Schally AM; Schally AV; Eckstein N; Vagman I; Limor R
Neuroendocrinology; 1993 Aug; 58(2):153-9. PubMed ID: 8264861
[TBL] [Abstract][Full Text] [Related]
16. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
[TBL] [Abstract][Full Text] [Related]
17. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K
Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692
[TBL] [Abstract][Full Text] [Related]
18. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men.
Behre HM; Böckers A; Schlingheider A; Nieschlag E
Clin Endocrinol (Oxf); 1994 Feb; 40(2):241-8. PubMed ID: 8137524
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats.
Pinski J; Yano T; Janaky T; Nagy A; Juhasz A; Bokser L; Groot K; Schally AV
Int J Pept Protein Res; 1993 Jan; 41(1):66-73. PubMed ID: 8436447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
